Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

verfasst von: M. Bouchahda, T. Macarulla, G. LIedo, F. Lévi, M. E. Elez, B. Paule, A. Karaboué, P. Artru, J. Tabernero, D. Machover, P. Innominato, E. Goldschmidt, D. Bonnet, M. Ducreux, V. Castagne, R. Guimbaud

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Cetuximab was approved using a weekly schedule, alone or in combination with chemotherapy (CT). However, many CT regimens in metastatic colorectal cancer (CRC) are delivered every 2 weeks (q2wks). Preliminary data suggested that a simplified schedule using cetuximab q2wks, 500 mg/m² would be equivalent to the standard weekly administration. Medical data of all patients with advanced CRC who received cetuximab q2wks were retrospectively collected and checked for consistency by an independent monitor in 4 European centers. Ninety-one patients were treated between 2005 and 2007 when the K-RAS mutational status of tumors was not determined routinely. They received a median of 4 (0–5) previous drugs, including previous weekly cetuximab in 38.5% of patients. Cetuximab q2wks was associated with an irinotecan-based regimen in 85.7% of patients. The median number of cetuximab administrations was 6 (1–23). Skin toxicity was observed in 68.2% of evaluable patients (grade 3 in 15%). Only one grade 1 allergy was reported. In the 84 patients beyond first-line therapy, response rate was 29.3%. The median progression-free survival was 3.0 months (range 2.2–3.8), and median overall survival was 9.0 months (range 6.2–11.8). Cetuximab q2wks appears safe and effective in heavily pretreated patients and convenient in combination with q2wks CT schedules.
Literatur
1.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:391–2.CrossRef Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:391–2.CrossRef
2.
Zurück zum Zitat Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914–21.PubMedCrossRef Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914–21.PubMedCrossRef
3.
Zurück zum Zitat Gebbia V, Del Prete S, Borsellino N, et al. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer. 2006;5(6):422–8.PubMedCrossRef Gebbia V, Del Prete S, Borsellino N, et al. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer. 2006;5(6):422–8.PubMedCrossRef
4.
Zurück zum Zitat Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225–32.PubMedCrossRef Tabernero J, Van Cutsem E, Díaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225–32.PubMedCrossRef
5.
Zurück zum Zitat Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6(2):S42–6.PubMedCrossRef Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6(2):S42–6.PubMedCrossRef
6.
Zurück zum Zitat Di Fiore F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166–9.PubMedCrossRef Di Fiore F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166–9.PubMedCrossRef
7.
Zurück zum Zitat De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.PubMedCrossRef De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508–15.PubMedCrossRef
8.
Zurück zum Zitat Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (c) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1wk) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2006; 24 (Supl 18S):142s (Abstr 3085). Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (c) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1wk) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2006; 24 (Supl 18S):142s (Abstr 3085).
9.
Zurück zum Zitat Pfeiffer P, Bjerregaard JK, Qvortrup C, et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60-min infusion.). J Clin Oncol 2007; 25 (Supl 18S):196s (Abstr 4133). Ann Oncol 2008; 19 (6):1141–1145. Pfeiffer P, Bjerregaard JK, Qvortrup C, et al. Simplification of cetuximab (Cet) administration: double dose every second week as a 60-min infusion.). J Clin Oncol 2007; 25 (Supl 18S):196s (Abstr 4133). Ann Oncol 2008; 19 (6):1141–1145.
10.
Zurück zum Zitat Lévi F, Karaboué A, Gorden L, et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2010; Epub ahead of print. Lévi F, Karaboué A, Gorden L, et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2010; Epub ahead of print.
11.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone: a multicenter randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone: a multicenter randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef
12.
Zurück zum Zitat de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMed de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMed
13.
Zurück zum Zitat Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRef Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.PubMedCrossRef
14.
Zurück zum Zitat Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779–86.PubMedCrossRef Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779–86.PubMedCrossRef
15.
Zurück zum Zitat de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007;25:3224–9.PubMedCrossRef de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007;25:3224–9.PubMedCrossRef
16.
Zurück zum Zitat Scartozzi M, Sobrero A, Gasparini G, et al. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. Oncology. 2005;68:212–6.PubMedCrossRef Scartozzi M, Sobrero A, Gasparini G, et al. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. Oncology. 2005;68:212–6.PubMedCrossRef
Metadaten
Titel
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis
verfasst von
M. Bouchahda
T. Macarulla
G. LIedo
F. Lévi
M. E. Elez
B. Paule
A. Karaboué
P. Artru
J. Tabernero
D. Machover
P. Innominato
E. Goldschmidt
D. Bonnet
M. Ducreux
V. Castagne
R. Guimbaud
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9716-8

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.